| Project/Area Number |
21590994
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMIZU Eiji 鳥取大学, 医学部, 教授 (50187449)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 肺癌 / 薬剤反応性 / 内科 / 薬剤反応 |
|---|
| Research Abstract |
An anti-EGFR monoclonal antibody, cetuximab, has been developed as a novel molecular targeting therapy in lung cancer. In this study, we developed a novel biomarker for cetuximab to select the subset of patients who will show a meaningful clinical response, by using our original finding that the main anti-cancer mechanism of cetuximab is immunological antitumor activity such as antibody-dependent cellular cytotoxicity(ADCC). As a result, we revealed that ULBP2 is the most significant NKG2D ligands, which are known as the activating ligands of NK cells, and that soluble form of ULBP2(sULBP2) directly suppresses both the cytolytic activity and cetuximab induced ADCC activity of host NK cells. Therefore, administration of cetuximab to the patients with low levels of sULBP, or the patients after surgery or chemotherapy with lowest sULBP2 levels is the best strategy for cetuximab treatment for lung cancer.
|
